New-onset hallucinations with amiodarone: a case report.

Amiodarone Case report Hallucinations Psycho-oncology

Journal

Annals of general psychiatry
ISSN: 1744-859X
Titre abrégé: Ann Gen Psychiatry
Pays: England
ID NLM: 101236515

Informations de publication

Date de publication:
24 Aug 2022
Historique:
received: 08 12 2021
accepted: 13 07 2022
entrez: 24 8 2022
pubmed: 25 8 2022
medline: 25 8 2022
Statut: epublish

Résumé

Amiodarone is a commonly used antiarrhythmic for the treatment of atrial fibrillation with a unique pharmacokinetic profile. While general side effects can be frequently associated with amiodarone, psychiatric adverse reactions to this medication are uncommon. The relationship between amiodarone and hallucinations independent of delirium has been rarely reported in the literature. We report the case of a 63-year-old female with a history of estrogen and progesterone receptor positive invasive ductal carcinoma with osseous metastases to the ribs and skull, major depressive disorder, and unspecified anxiety. She was diagnosed with invasive ductal carcinoma 12 years prior and underwent a lumpectomy with axillary lymph node dissection and radiation, currently maintained on anastrozole and trastuzumab for the past 11 years. Her symptoms of major depressive disorder and anxiety have remained in remission on a regimen of bupropion extended release, duloxetine, and trazodone without recent dose changes. This patient presented to the emergency department with dyspnea and was admitted to the general medical floor with new-onset atrial fibrillation. She was subsequently started on amiodarone for rhythm control. Shortly after its initiation, the patient developed new onset auditory and visual hallucinations with an unremarkable extensive medical evaluation. Auditory hallucinations consisted of music and unintelligible conversations, while visual hallucinations were of a family member crying on the floor and a man carrying a gun. The differential diagnoses included depression with psychotic features, delirium, and amiodarone-induced hallucinations. Given the lack of current depressive symptoms, absence of altered cognition, and the temporal relationship between the initiation of amiodarone and the onset of hallucinations, amiodarone was suspected to be probable etiology of her hallucinations. For this reason, amiodarone was replaced with dronedarone. Visual and auditory hallucinations ceased within less than 3 days after the discontinuation of amiodarone. Psychiatric adverse events from amiodarone are uncommon, and associated isolated hallucinations have only been rarely reported in the literature. While the risk of visual and auditory hallucinations appears to be low with amiodarone initiation, clinicians should be aware of this potential side effect.

Sections du résumé

BACKGROUND BACKGROUND
Amiodarone is a commonly used antiarrhythmic for the treatment of atrial fibrillation with a unique pharmacokinetic profile. While general side effects can be frequently associated with amiodarone, psychiatric adverse reactions to this medication are uncommon. The relationship between amiodarone and hallucinations independent of delirium has been rarely reported in the literature.
CASE PRESENTATION METHODS
We report the case of a 63-year-old female with a history of estrogen and progesterone receptor positive invasive ductal carcinoma with osseous metastases to the ribs and skull, major depressive disorder, and unspecified anxiety. She was diagnosed with invasive ductal carcinoma 12 years prior and underwent a lumpectomy with axillary lymph node dissection and radiation, currently maintained on anastrozole and trastuzumab for the past 11 years. Her symptoms of major depressive disorder and anxiety have remained in remission on a regimen of bupropion extended release, duloxetine, and trazodone without recent dose changes. This patient presented to the emergency department with dyspnea and was admitted to the general medical floor with new-onset atrial fibrillation. She was subsequently started on amiodarone for rhythm control. Shortly after its initiation, the patient developed new onset auditory and visual hallucinations with an unremarkable extensive medical evaluation. Auditory hallucinations consisted of music and unintelligible conversations, while visual hallucinations were of a family member crying on the floor and a man carrying a gun. The differential diagnoses included depression with psychotic features, delirium, and amiodarone-induced hallucinations. Given the lack of current depressive symptoms, absence of altered cognition, and the temporal relationship between the initiation of amiodarone and the onset of hallucinations, amiodarone was suspected to be probable etiology of her hallucinations. For this reason, amiodarone was replaced with dronedarone. Visual and auditory hallucinations ceased within less than 3 days after the discontinuation of amiodarone.
CONCLUSIONS CONCLUSIONS
Psychiatric adverse events from amiodarone are uncommon, and associated isolated hallucinations have only been rarely reported in the literature. While the risk of visual and auditory hallucinations appears to be low with amiodarone initiation, clinicians should be aware of this potential side effect.

Identifiants

pubmed: 36002899
doi: 10.1186/s12991-022-00409-y
pii: 10.1186/s12991-022-00409-y
pmc: PMC9400302
doi:

Types de publication

Journal Article

Langues

eng

Pagination

34

Informations de copyright

© 2022. The Author(s).

Références

Epilepsy Behav. 2005 May;6(3):413-6
pubmed: 15820351
Dialogues Clin Neurosci. 2007;9(1):29-45
pubmed: 17506224
Psychosomatics. 2013 May-Jun;54(3):294-6
pubmed: 23218061
Therapie. 2007 Jul-Aug;62(4):357-9
pubmed: 18077897
J Am Board Fam Med. 2008 May-Jun;21(3):244-5
pubmed: 18467537
Am J Geriatr Psychiatry. 2003 Nov-Dec;11(6):696-7
pubmed: 14609814
Br J Psychiatry. 1999 Apr;174:366-7
pubmed: 10533558
Ann Intern Med. 1988 Jan;108(1):68-9
pubmed: 3337520
J Oncol Pharm Pract. 2019 Apr;25(3):754-757
pubmed: 29536789
J R Soc Med. 1988 May;81(5):296-7
pubmed: 3385716
Am J Psychiatry. 1999 Jul;156(7):1119
pubmed: 10401472
J Psychopharmacol. 2010 Jan;24(1):131-3
pubmed: 18801834
Indian J Psychiatry. 2015 Jan-Mar;57(1):105-6
pubmed: 25657475
Curr Drug Saf. 2017;12(3):193-197
pubmed: 28699493
Am Fam Physician. 2003 Dec 1;68(11):2189-96
pubmed: 14677664
J Geriatr Cardiol. 2019 Jul;16(7):552-566
pubmed: 31447894
Pol Merkur Lekarski. 2021 Oct 22;49(293):361-363
pubmed: 34800024

Auteurs

Jessica Molinaro (J)

Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI, 53226, USA. jmolinaro@mcw.edu.

Peter DeVries (P)

Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI, 53226, USA.

Jennifer Ha (J)

Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI, 53226, USA.

Jennifer M Knight (JM)

Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI, 53226, USA.
Departments of Medicine and Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.

Classifications MeSH